Friday, Jun 16, 2000
South San Francisco, Calif. -- June 16, 2000 --Genentech, Inc. (NYSE: DNA) announced today preliminary results that the 415-patient Phase II clinical trial of the company's recombinant humanized anti-CD18 monoclonal antibody fragment (rhuMAb CD18) for the treatment of myocardial infarction (heart attack) did not meet its primary objectives.
Detailed trial results will be presented during the European Society of Cardiology meeting in August, 2000, in Amsterdam, The Netherlands.
"We are disappointed in the preliminary analysis of the data, as in the pre-clinical setting it appeared that the anti-CD18 antibody might have an important role in reducing the cardiovascular damage that occurs during a myocardial infarction," said Susan D. Hellmann, M.D., M.P.H., Genentech's executive vice president, Development and Product Operations, and chief medical officer. "However, we plan to meet with our investigators this summer to evaluate the implications of the data, and we remain committed to developing and improving treatments for patients experiencing heart attack."
Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Thirteen of the approved products of biotechnology stem from Genentech science. Genentech markets eight products directly in the United States. The company has headquarters in South San Francisco, California, and is traded on the New York Stock Exchange under the symbol DNA.
# # #